Q1: A flood of investor cash drove biotech's numbers to new record highs, and the torrent of cash is moving upstream fast
If you thought biotech was booming last year, wait until you get a load of the numbers from Q1 2021.
On virtually every level, with one exception, the money engine was working around the clock in the first 3 months of this year. Venture capital has reached such a fever peak that the average B round now weighs in at an average mega-weight value of $100 million. The money flow is also finding its way to the mouth of the R&D river, where discovery work now merits the big bucks instead of cautionary seed funds.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.